Sovaldi® (sofosbuvir) – Expanded orphan indication, new formulation approval
August 28, 2019 - The FDA approved Gilead’s Sovaldi (sofosbuvir), for the treatment of chronic hepatitis C virus (HCV) genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.
Top